NovoCure (FRA:038) Retained Earnings: €-1,195.4 Mil (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

FRA:038 NovoCure Ltd FRA:038
70 GF Score
Price €14.59
GF Value €16.63
Valuation Fairly Valued
! 4 Warning Signs
View Full Analysis

What is NovoCure Retained Earnings?

NovoCure FRA:038 +11.84% 70 Retained Earnings is €-1,195.4 Mil as of Jun. 2026. GuruFocus rates FRA:038 with a GF Score™ of 70/100 and a GF Value™ of €16.63 (Fairly Valued). The stock has 4 warning signs investors should review.

Retained earnings is the accumulated portion of net income that is not distributed to shareholders. NovoCure's retained earnings for the quarter that ended in Jun. 2026 was €-1,195.4 Mil.

NovoCure's quarterly retained earnings declined from Dec. 2025 (€-1,102.0 Mil) to Mar. 2026 (€-1,177.7 Mil) and declined from Mar. 2026 (€-1,177.7 Mil) to Jun. 2026 (€-1,195.4 Mil).

NovoCure's annual retained earnings declined from Dec. 2023 (€-903.7 Mil) to Dec. 2024 (€-1,102.2 Mil) but then increased from Dec. 2024 (€-1,102.2 Mil) to Dec. 2025 (€-1,102.0 Mil).


NovoCure  (FRA:038) Retained Earnings Explanation

Historically profitable companies sometimes have negative retained earnings. This is because they have cumulatively paid out more to shareholders than they reported in profits.

For example, in 2011, Microsoft had negative retained earnings. This does not mean the company lost more money than it made over the years. It just means it paid out more money than it earned.

If a company has negative retained earnings, investors should check the 10-year financial results. They should not assume that negative retained earnings prove a company has generally lost money in the past.

Of course, many companies with negative retained earnings have indeed lost money in the past.

Retained Earnings: Warren Buffett's Secret.

One of the most important indicators of durable competitive advantage. Net earnings can be paid out as dividends, used to buy back shares or retained for growth.

If the company loses more than it has accumulated, retained earnings is negative.

If a company isn't adding to its retained earnings, it isn't growing its net worth.

Rate of growth of retained earnings is good indicator whether it's benefiting from a competitive advantage.

Microsoft is negative because it chose to buyback stock and pay dividends.

The more earnings retained, the faster it grows and increases growth rate for future earnings.


NovoCure Retained Earnings Historical Data

* Premium members only.

The historical data trend for NovoCure's Retained Earnings can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

NovoCure Retained Earnings Chart

NovoCure Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Retained Earnings
Get a 7-Day Free Trial Premium Member Only Premium Member Only -607.05 -734.87 -903.71 -1,102.19 -1,101.97

NovoCure Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Retained Earnings Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -1,065.19 -1,078.51 -1,101.97 -1,177.69 -1,195.37
FRA:038
70GF Score
NovoCure Ltd FRA:038
Retained Earnings is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

NovoCure Retained Earnings Calculation

Retained Earnings is the accumulated portion of net income that is not distributed to shareholders. Because the net income was not distributed to shareholders, shareholders' equity is increased by the same amount.

Of course, if a company loses, it is called retained losses, or accumulated losses.

Frequently Asked Questions Learn more about Retained Earnings →
What does a Retained Earnings of €-1,195.4 Mil mean?
NovoCure (FRA:038) has a Retained Earnings of €-1,195.4 Mil as of Jun. 2026. Retained earnings is the amount of net income not issued to shareholders. View historical data on NovoCure and its competitors.
Is NovoCure's Retained Earnings too high?
NovoCure's current Retained Earnings is €-1,195.4 Mil. Overall, NovoCure has a GF Score™ of 70/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does NovoCure's Retained Earnings compare to NEOG and AXGN?
NovoCure's Retained Earnings of €-1,195.4 Mil can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Retained Earnings for a Medical Devices & Instruments company?
A good Retained Earnings depends on the Medical Devices & Instruments industry context. However, Retained Earnings should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Retained Earnings mean?
A high Retained Earnings can signal that a stock is expensive relative to its fundamentals. Retained earnings is the amount of net income not issued to shareholders. View historical data on NovoCure and its competitors. NovoCure's current Retained Earnings is €-1,195.4 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is NovoCure stock overvalued right now?
Based on GuruFocus' analysis, NovoCure (FRA:038) is currently considered Fairly Valued. The stock's GF Value™ is €16.63, compared to a current price of €14.59 — trading 12.3% below its estimated fair value. The current Retained Earnings is €-1,195.4 Mil. NovoCure's overall GF Score™ is 70/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Retained Earnings calculated?
Retained Earnings is calculated from a company's financial statements. For NovoCure (FRA:038), the current Retained Earnings is €-1,195.4 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is NovoCure (FRA:038) Overvalued in 2026?

Based on GuruFocus' analysis, NovoCure stock appears to be undervalued. The current stock price of €14.59 is trading 12.3% below its estimated GF Value™ of €16.63. GuruFocus considers NovoCure to be Fairly Valued.

Key valuation signals for FRA:038:

  • Retained Earnings: €-1,195.4 Mil
  • GF Value™: €16.63 vs. price of €14.59 (12.3% below fair value)
  • GF Score™: 70/100 with 4 warning signs

No single metric tells the full story. See the FRA:038 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


NovoCure Business Description

Address Grenville Street, No. 4 The Forum, Second Floor, St. Helier, JEY, JE2 4UF
NovoCure Ltd is an oncology company with a proprietary platform technology in the United States. Its business involves the development, manufacture, and commercialization of Tumor Treating Fields (TTFields) devices, including Optune Gio and Optune Lua, for the treatment of solid tumor cancers. Its pipeline consists of Trident, Lunar-2, Panova-3, Metis, and other products and technologies for the treatment of Glioblastoma, Non-small cell lung cancer, and Pancreatic cancer. Geographically, the company derives the majority of its revenue from the United States and the rest from Germany, Japan, and other markets.
70GF Score

Get the complete analysis for FRA:038

Retained Earnings is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€14.59
Price
€16.63
GF Value